-
In vivo CAR T cells move into clinical trials Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-16
Drug developers want to reprogramme immune cells directly in the body, opening up new gene therapy frontiers in cancer and autoimmunity.
-
Creating an AI-first drug discovery engine Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-13
Najat Khan — Chief R&D Officer and Chief Commercial Officer at Recursion — discusses the proposed merger of Recursion and Exscientia.
-
Author Correction: Antimalarial drug discovery: progress and approaches. Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-13 Jair L Siqueira-Neto,Kathryn J Wicht,Kelly Chibale,Jeremy N Burrows,David A Fidock,Elizabeth A Winzeler
-
Targeting cytokine networks in neuroinflammatory diseases Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-11 Burkhard Becher, Tobias Derfuss, Roland Liblau
-
Upcoming market catalysts in Q4 2024 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-10
Discover the world’s best science and medicine | Nature.com
-
Neurons give metastatic cells a push Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-09
Discover the world’s best science and medicine | Nature.com
-
Splice-switching ASO curtails brain calcification Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-09
Discover the world’s best science and medicine | Nature.com
-
PPAR agonists provide new treatment options for inflammatory liver disease Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-09
Discover the world’s best science and medicine | Nature.com
-
RIPTACs expand anticancer target space Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-09
Discover the world’s best science and medicine | Nature.com
-
Organoids identify a role for IL-7 in coeliac disease Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-09
Discover the world’s best science and medicine | Nature.com
-
Understanding anellovirus immune evasion Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-06
Discover the world’s best science and medicine | Nature.com
-
Apolipoprotein L2 inhibitor mitigates fibrosis Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-06
Discover the world’s best science and medicine | Nature.com
-
Targeting the peripheral neural-tumour microenvironment for cancer therapy Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-06 Dan Yaniv, Brandi Mattson, Sebastien Talbot, Frederico O. Gleber-Netto, Moran Amit
-
Protein isoform-centric therapeutics: expanding targets and increasing specificity Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-04 Peter Kjer-Hansen, Tri Giang Phan, Robert J. Weatheritt
-
Engineered parasite delivers proteins to the brain Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-08-23
Discover the world’s best science and medicine | Nature.com
-
Degrading cell-free DNA to prevent recurrent stroke Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-08-22
Discover the world’s best science and medicine | Nature.com
-
FDA approves IDH1 and IDH2 inhibitor for brain cancer Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-08-16
Discover the world’s best science and medicine | Nature.com
-
FDA approves first TCR-engineered T cell therapy, for rare soft-tissue cancer Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-08-16
Discover the world’s best science and medicine | Nature.com
-
A golden age of muscarinic acetylcholine receptor modulation in neurological diseases Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-08-14 Andrew B. Tobin
-
The breast cancer drug market Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-08-13
Discover the world’s best science and medicine | Nature.com
-
Comprehensive measurement of biopharmaceutical R&D investment Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-08-06
Discover the world’s best science and medicine | Nature.com
-
Per-patient approach to calculating drug development costs yields lower estimate Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-08-05
Discover the world’s best science and medicine | Nature.com
-
Anti-IL-11 antibody shows anti-ageing properties Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-08-01
Discover the world’s best science and medicine | Nature.com
-
Chinese innovative drug R&D trends in 2024 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-31
Discover the world’s best science and medicine | Nature.com
-
Muscarinic drugs breathe new life into schizophrenia pipeline Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-30
Karuna and Bristol Myers Squibb’s muscarinic agonist KarXT looks set to offer the first new drug mechanism for patients with schizophrenia in over 70 years.
-
TCR-boosted T cell therapy yields proof-of-principle clinical data in solid cancer Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-29
Discover the world’s best science and medicine | Nature.com
-
Epigenetic editor silences prion protein Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-25
Discover the world’s best science and medicine | Nature.com
-
Oral miniproteins treat IBD Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-25
Discover the world’s best science and medicine | Nature.com
-
Proteogenomics identifies anticancer targets Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-25
Discover the world’s best science and medicine | Nature.com
-
Opioid antidote gets a boost Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-25
Discover the world’s best science and medicine | Nature.com
-
Antibody sniffs out tau Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-23
Discover the world’s best science and medicine | Nature.com
-
AI reverse-engineers antibodies Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-23
Discover the world’s best science and medicine | Nature.com
-
Molecular glue degrader for sickle cell disease Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-23
Discover the world’s best science and medicine | Nature.com
-
New epilepsy therapies in development Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-22 Pavel Klein, Rafal M. Kaminski, Matthias Koepp, Wolfgang Löscher
-
Author Correction: Sequential immunotherapy: towards cures for autoimmunity. Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-01 Francisco Ramírez-Valle,Joseph C Maranville,Sophie Roy,Robert M Plenge
-
Eli Lilly spends $3.2 billion on Morphic's oral integrin inhibitor for inflammatory bowel disease. Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-01 Asher Mullard
-
Show them the money: a multi-stakeholder perspective on reforming clinical trial participant compensation. Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-18 Gunnar Esiason,Angela Pontius,Luke Gelinas
-
Chromatin remodellers as therapeutic targets Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-16 Hayden A. Malone, Charles W. M. Roberts
-
Data science in pharmaceutical R&D: the DISRUPT-DS industry roundtable Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-15 Najat S. Khan, Thomas Senderovitz, James Weatherall, Janice Branson, Benedikt Egersdoerfer, Eric Genevois-Marlin, Sai Jasti, Mustaqhusain Kazi, Ranjit Kumble, Patrick Loerch, Justine Rochon, Venkat Sethuraman, Matt Studney, Xiaoying Wu, Ryan Copping, Priya Chandran, Dhruv Jayanth, Christoph Meier
The DISRUPT-DS roundtable, which brings together data science leaders from large pharmaceutical companies, aims to be a forum for sharing experiences and networking, for shaping industry-level topics and for amplifying the role of data science across pharmaceutical R&D.
-
FDA new drug approvals in Q2 2024 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-15
Discover the world’s best science and medicine | Nature.com
-
A rush of CRISPR to the lungs Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-10
Discover the world’s best science and medicine | Nature.com
-
Targeting ROS in cancer: rationale and strategies Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-09 Christophe Glorieux, Shihua Liu, Dunyaporn Trachootham, Peng Huang
-
FDA approves third anti-amyloid antibody for Alzheimer disease Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-05
Discover the world’s best science and medicine | Nature.com
-
Rebalancing calcium in Alzheimer disease Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-05
Discover the world’s best science and medicine | Nature.com
-
The 60-year evolution of lipid nanoparticles for nucleic acid delivery Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-04 P. R. Cullis, P. L. Felgner
-
Enhancing in situ cancer vaccines using delivery technologies Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-01 Ningqiang Gong, Mohamad-Gabriel Alameh, Rakan El-Mayta, Lulu Xue, Drew Weissman, Michael J. Mitchell
-
When chronic and rare disease worlds converge Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-27
Sharon Barr, head of BioPharmaceuticals R&D at AstraZeneca, discusses her chronic disease research priorities, including the need for new diagnostic tools, fixed-dose drugs and a better understanding of disease biology.
-
Machine learning identifies AMPs Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-27
Discover the world’s best science and medicine | Nature.com
-
Discovering CFTR modulators Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-27
Discover the world’s best science and medicine | Nature.com
-
ETS2 drives IBD Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-27
Discover the world’s best science and medicine | Nature.com
-
A selective microbiome-sparing antibiotic Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-27
Discover the world’s best science and medicine | Nature.com
-
Gene therapies start the climb from rare disease base camps to common disease peaks Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-25
Jude Samulski, former CSO and co-founder of AskBio, discusses the future of gene therapy for complex and common diseases, including Parkinson disease and congestive heart failure.
-
FDA approves 21-valent pneumococcal vaccine Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-21
Discover the world’s best science and medicine | Nature.com
-
Menin inhibitors seek to debut as newest targeted therapy for leukaemia Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-21
Small molecules that block a key protein–protein interaction could change the treatment landscape for many patients with acute leukaemias.
-
CAR T cells take to the airways Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-19
Discover the world’s best science and medicine | Nature.com
-
Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-18 Terry Kenakin
-
Extracellular targeted protein degrader removes antibodies in first test in humans Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-18
Biohaven’s BHV-1300 lowered levels of immunoglobulin G in the blood of healthy volunteers — a first clinical demonstration of the potential of a small-molecule extracellular protein degrader.
-
FDA approves first telomerase inhibitor Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-14
Discover the world’s best science and medicine | Nature.com
-
Upcoming market catalysts in Q3 2024 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-12
Discover the world’s best science and medicine | Nature.com
-
Chromatin-targeted drug discovery at “a very special moment” Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-11
Cigall Kadoch, a cancer researcher at Dana-Farber Cancer Institute and co-founder of Foghorn Therapeutics, discusses the case for a new wave of epigenetic drugs, targeting chromatin remodelling complexes.